Androgen News and Research RSS Feed - Androgen News and Research

Sanford-Burnham to present new cancer research data at AACR 2014

Sanford-Burnham to present new cancer research data at AACR 2014

Sanford-Burnham Medical Research Institute will present a wide range of new research data at the annual American Association for Cancer Research Meeting in San Diego starting Saturday, April 5, at the San Diego Convention Center. The presentations will cover a variety of topics including breast, melanoma, and prostate cancer, as well as novel methods of delivering drugs to tumors. [More]
NCCN ORP awarded grant to study effectiveness of enzalutamide in solid tumors

NCCN ORP awarded grant to study effectiveness of enzalutamide in solid tumors

The National Comprehensive Cancer Network Oncology Research Program has been awarded a $2.2-million grant from Astellas Pharma, Inc. and Medivation, Inc. to develop a program to scientifically evaluate and define the clinical effectiveness of enzalutamide in solid tumors, including bladder, breast, endometrial, hepatocellular, ovarian, and prostate cancers. [More]
Clinical trials of new drugs to treat most aggressive form of prostate cancer

Clinical trials of new drugs to treat most aggressive form of prostate cancer

Clinical trials of new drugs to treat the most aggressive form of prostate cancer are expected to be underway in Brisbane within three years, thanks to Movember Revolutionary Team Award grant that is fast-tracking global research into the disease. [More]
Datamonitor Healthcare: Over half a million prostate cancer incident cases to be diagnosed this year

Datamonitor Healthcare: Over half a million prostate cancer incident cases to be diagnosed this year

Over half a million cases of prostate cancer will be diagnosed worldwide in 2014, according to new research from global independent analyst firm Datamonitor Healthcare. [More]
Primary ADT proves ineffective in early stage prostate cancer patients

Primary ADT proves ineffective in early stage prostate cancer patients

A study of more than 15,000 men with early stage prostate cancer finds that those who received androgen deprivation as their primary treatment instead of surgery or radiation did not live any longer than those who received no treatment. [More]
Synta Pharmaceuticals' Hsp90 inhibitor ganetespib selected for study in I-SPY 2 TRIAL

Synta Pharmaceuticals' Hsp90 inhibitor ganetespib selected for study in I-SPY 2 TRIAL

Synta Pharmaceuticals Corp. and QuantumLeap Healthcare Collaborative today announced that Synta's lead drug candidate, the Hsp90 inhibitor ganetespib, has been selected for study in the I-SPY 2 TRIAL (Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging And moLecular Analysis 2). [More]
Scientists identify important step toward shutting down growth of prostate cancer cells

Scientists identify important step toward shutting down growth of prostate cancer cells

Scientists at UT Southwestern Medical Center have identified an important step toward potentially shutting down the growth of prostate cancer cells. [More]
New study shows male hormones play important role; may enhance IVF therapy in women

New study shows male hormones play important role; may enhance IVF therapy in women

Several fertility clinics across the country are beginning to administer testosterone, either through a patch or a gel on the skin, to increase the number of eggs produced by certain women undergoing in vitro fertilization (IVF). [More]
GTx provides clinical updates, reports financial results for fourth quarter and full year 2013

GTx provides clinical updates, reports financial results for fourth quarter and full year 2013

GTx, Inc. today provided a Company update and reported financial results for the fourth quarter and full year 2013. [More]
Exposure to very low concentrations of BPA by pregnant females can cause fetal abnormalities in primates

Exposure to very low concentrations of BPA by pregnant females can cause fetal abnormalities in primates

Bisphenol A (BPA) is a chemical that is used in a wide variety of consumer products, such as resins used to line metal food and beverage containers, thermal paper store receipts, and dental composites. [More]
UH scientists working to develop next generation of prostate cancer therapies

UH scientists working to develop next generation of prostate cancer therapies

A University of Houston scientist and his team are working to develop the next generation of prostate cancer therapies, which are targeted at metabolism. [More]
Robotic-assisted radical prostatectomy shows better outcomes in cancer removal

Robotic-assisted radical prostatectomy shows better outcomes in cancer removal

An observational study from UCLA's Jonsson Comprehensive Cancer comparing robotic-assisted prostate surgery to open surgery for prostate cancer found that patients who had robotic surgery had fewer instances of cancer cells at the edge of the surgical specimen, or fewer positive margins, and less need of additional cancer treatments, such as hormone therapy or radiation, than patients who had open surgery. [More]
Researchers develop screening assay that quickly assesses nearly 1,500 compounds' effect on estrogen

Researchers develop screening assay that quickly assesses nearly 1,500 compounds' effect on estrogen

A team of researchers at City of Hope has developed a screening assay that can quickly assess up to 1,536 compounds' effect on estrogen activity in the body. The test can also evaluate whether chemicals act as inhibitors of aromatase, an enzyme linked to breast cancer that converts androgen to estrogen. [More]
Understanding genetic changes associated with aggressive prostate cancer

Understanding genetic changes associated with aggressive prostate cancer

Researchers at the University of East Anglia have made an important advance in understanding genetic changes associated with terminal prostate cancer. [More]
Mayo Clinic researchers shed light on new mechanism by which prostate cancer develops in men

Mayo Clinic researchers shed light on new mechanism by which prostate cancer develops in men

Mayo Clinic researchers have shed light on a new mechanism by which prostate cancer develops in men. Central to development of nearly all prostate cancer cases are malfunctions in the androgen receptor - the cellular component that binds to male hormones. [More]
Findings expand treatment options for hormone-dependent breast cancer

Findings expand treatment options for hormone-dependent breast cancer

According to the United States Centers for Disease Control and Prevention, breast cancer is the most common cancer in women. For patients whose breast cancers are hormone-dependent, current treatment focuses on using drugs that block estrogen (a type of hormone) from attaching to estrogen receptors on tumor cells to prevent the cells from growing and spreading. [More]
Prostate cancer patients treated with ADT experience mental, emotional well-being during treatment

Prostate cancer patients treated with ADT experience mental, emotional well-being during treatment

‚ÄčA new study published in the Journal of Urology- reports that prostate cancer patients treated with androgen deprivation therapy (ADT) experienced changes in mental and emotional well-being during treatment, although there was no meaningful decline in emotional quality of life two years after treatment. [More]
Prostate cancer vaccines receive a boost in funding

Prostate cancer vaccines receive a boost in funding

The development of two innovative new vaccines that are hoped to offer an alternative to castration therapy for men with recurring prostate cancer, is due for an $8 million boost in funding. [More]
Synta initiates three multicenter trials to evaluate ganetespib with chemotherapy for AML and MDS

Synta initiates three multicenter trials to evaluate ganetespib with chemotherapy for AML and MDS

Synta Pharmaceuticals Corp. today announced the initiation of three multicenter, randomized trials supported by the Leukemia & Lymphoma Research Fund and Cancer Research UK, evaluating ganetespib in combination with chemotherapy in first-line treatment of patients with AML and high risk MDS. [More]
Researchers investigate how androgen receptors affect prostate cancer progression

Researchers investigate how androgen receptors affect prostate cancer progression

Approximately 1 out of every 6 American men will be diagnosed with prostate cancer, and this year alone there are expected to be nearly a quarter of a million new cases diagnosed, making prostate cancer the most common malignancy among men in the United States. Center for Nuclear Receptors & Cell Signaling Assistant Professor Daniel Frigo and his research team recently published a study investigating the processes through which androgen receptors affect prostate cancer progression. [More]